



PRIMA BIOMED LTD

Australian Cancer Treatment Company

*Developing the world's first Ovarian Cancer
Therapy Vaccine*

JP Morgan Healthcare San Francisco - January 2010

*Cell Therapy – A new paradigm
for the treatment of cancer*



Important Notice

The purpose of the presentation is to provide an update of the business of Prima Biomed Ltd ACN 009 237 889 (ASX:PRR) (Prima). These slides have been prepared as a presentation aid only and the information they contain may require further explanation and/or clarification. Accordingly, these slides and the information they contain should be read in conjunction with past and future announcements made by Prima and should not be relied upon as an independent source of information. Please contact Prima and/or refer to the Company's website for further information.

The views expressed in this presentation contain information derived from publicly available sources that have not been independently verified. No representation or warranty is made as to the accuracy, completeness or reliability of the information. Any forward looking statements in this presentation have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside Prima Biomed Ltd's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this presentation include known and unknown risks. Because actual results could differ materially to assumptions made and Prima Biomed's current intentions, plans, expectations and beliefs about the future, you are urged to view all forward looking statements contained in this presentation with caution. This presentation should not be relied on as a recommendation or forecast by Prima Biomed Limited. Nothing in this presentation should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

**Cell Therapy – A new paradigm
for the treatment of cancer**



About Prima Biomed

Prima BioMed (ASX:PRR) is an Australian biotechnology company focused on **cancer immunotherapy**, which stimulates the body's own immune system to attack tumors.

Its lead product is the **CVac™ ovarian cancer vaccine** - a maintenance therapy vaccine administered post-surgery and post-chemotherapy to delay relapse and control metastases.

- Phase I and IIa clinical trials successfully concluded
- Planning & approvals for Phase IIb/III trials underway and trials to begin 2010

Prima's **extensive intellectual property portfolio** originates from the Austin Research Institute, Melbourne. The Company's **strategy is to commercialise CVac™ into the multi-billion dollar global pharmacy oncology market** and partner-out non-core immunology assets.

*Cell Therapy – A new paradigm
for the treatment of cancer*



Demand for CVac™

- The global market size of ovarian cancer is estimated to grow to **US\$3.6b by 2010**
- Each year **73,000 women** are diagnosed with ovarian cancer in the US, Europe, Australia and Japan. **318,000 globally**
- Of this number, **only 10% survive beyond 5 years**
- A maintenance style treatment like CVac™ would be the first of its type in the market and would initially aim to take a conservative 10-25% of this ovarian cancer treatment market
- 76% of patients relapse within a year of chemotherapy
- Non-toxic nature of CVac™ creates a “no-brainer” for the oncologist
- **A conservative 10% market share equates to approximately US\$360m p.a. Wall St analysts of DNDN suggest market size could be greater than US\$1.5Bn per indication**
- CVac™ also has further indications across a number of other cancers



Value Drivers

- ✓ CVac™ addresses a major global un-met medical need
- ✓ Ovarian cancer has a very high morbidity rate and currently there are no maintenance treatments commercially available
- ✓ Global ovarian cancer treatment market estimated to be worth US\$3.6b in 2010
- ✓ Investigational New Drug (IND) application lodged with US FDA
- ✓ Approval to commence Phase IIb clinical trial granted by FDA and trial to start early 2010
- ✓ Phase IIb trial to be managed from prestigious Fred Hutchinson Cancer Centre in Seattle in the USA on a 60 patient population
- ✓ **Progressing rapidly to commercialisation of world's first ovarian cancer vaccine therapy, Cvac™**



Value Drivers

- ✓ Pursuing fast-track commercialisation in other jurisdictions outside US FDA
- ✓ Phase III clinical trial to be conducted in Europe, in 2010 also
- ✓ Have commenced selected treatment of patients in Australia
- ✓ World class scientific advisory team including Prof Ian Frazer, co-inventor of Merck/CSL's cervical cancer vaccine, Gardasil™
- ✓ Leading pharmaceutical sector expert Dr Neil Frazer appointed Chief Medical Officer to oversee CVac™ clinical trials
- ✓ Company to also develop an oral delivery system for cervical cancer vaccine
- ✓ Company well funded; **A\$25.5m** equity funding from US fund, and **A\$11.25m** raised from recent Share Purchase Plan



Corporate Overview

Issued Capital

ASX Code:	PRR
Shares:	628.6M
Listed Options:	127.4M (exercise price \$0.02 on or before 31 Dec 2011)
Total Issued Securities:	727.0M

Price & Capitalisation

Share Price:	15c (31/12/09)
2009 high:	28.5c (08/10/09)
Mkt. Cap	\$97.6M
Cash Position:	\$14.36M

Board of Directors

Mr Ata Gokyildirim	Chairman
Mr Martin Rogers	Chief Executive Officer
Dr Richard Hammel	Non-Executive Director

*Cell Therapy – A new paradigm
for the treatment of cancer*



Contact



PRIMABioMed
LIMITED

Dr. Richard Hammel, Non-Executive Director
Ph(US): +1 510 919 2385

Martin Rogers, CEO

Ph: +61 3 9824 5254

Mob: +61 428 268 357

E: martin.rogers@primabiomed.com.au

W: www.primabiomed.com.au

*Cell Therapy – A new paradigm
for the treatment of cancer*